Jpmorgan Chase & CO Orchard Therapeutics PLC Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.36 - $0.49 $1,937 - $2,637	-5,383 Reduced 2.42%	217,166 $81,000
Q3 2022 Nov 14, 2022	SELL	$0.45 - $0.69 $618,327 - $948,102	-1,374,062 Reduced 86.06%	222,549 $111,000
Q2 2022 Aug 11, 2022	SELL	$0.42 - $0.78 $44,416 - $82,487	-105,753 Reduced 6.21%	1,596,611 $933,000
Q1 2022 May 11, 2022	SELL	$0.7 - $1.51 $98,889 - $213,317	-141,270 Reduced 7.66%	1,702,364 $1.21 Million
Q4 2021 Feb 10, 2022	SELL	$1.16 - $2.23 $1.59 Million - $3.06 Million	-1,374,031 Reduced 42.7%	1,843,634 $2.43 Million
Q3 2021 Nov 12, 2021	BUY	$2.24 - $4.29 $7.21 Million - $13.8 Million	3,217,665 New	3,217,665 $7.4 Million

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.